Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intermittent vs Continuous Venetoclax with Acalabrutinib in Untreated CLL/SLL
NCT07014917Phase 2Recruiting
- Start
- Dec 2025
- Primary completion
- Jun 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of venetoclax in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL). Started Dec 2025; status: recruiting.
02
Drugs
venetoclax
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT07014917.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07014917.